December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by D&D Pharmatech, Inc.

News headline image
D&D Pharmatech Announces Positive 48-Week Histology Results for Zabopegdutide (DD01), Demonstrating Statistically Significant Fibrosis Improvement and MASH Resolution
From D&D Pharmatech, Inc.
Via Business Wire
News headline image
D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health
From D&D Pharmatech, Inc.
Via Business Wire
News headline image
D&D Pharmatech Announces Completion of Patient Enrollment for a 48-Week Phase 2 Trial Evaluating the Effectiveness of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist, in the Treatment of MASH
From D&D Pharmatech, Inc.
Via Business Wire
News headline image
D&D Pharmatech Announces Initiation of Dosing in a Phase 2 Trial Designed to Evaluate the Efficacy and Safety of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist in Overweight/Obese Subjects with MASLD/MASH
From D&D Pharmatech, Inc.
Via Business Wire
News headline image
D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH
From D&D Pharmatech, Inc.
Via Business Wire
News headline image
D&D Pharmatech Announces Rapid, Clinically Significant Reductions in Liver Fat Achieved in Four Weeks Treating NAFLD Patients with DD01, a Novel Long-Acting GLP-1/Glucagon Receptor Agonist
From D&D Pharmatech, Inc.
Via Business Wire
News headline image
D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China
From D&D Pharmatech, Inc.
Via Business Wire
News headline image
D&D Pharmatech Appoints Yoo-Seok Hong as Chief Executive Officer
From D&D Pharmatech, Inc.
Via Business Wire
News headline image
D&D Pharmatech Announces Sponsored Research Agreement with Yale University to Optimize Novel Strategies for the Treatment of Brain Cancer and Other Diseases of the Central Nervous System
From D&D Pharmatech, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.